Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • Log out
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • Log out
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
Meeting ReportRadiopharmaceutical Chemistry: New Radiopharmaceuticals-Neurosciences

Synthesis and evaluation of I-125 quinolinone analogues as potential oxytocin receptor biomarkers

Aaron Smith, Sara Freeman, Ronald Voll, Jeff Stehouwer, Larry Young and Mark Goodman
Journal of Nuclear Medicine May 2010, 51 (supplement 2) 1503;
Aaron Smith
1Radiology, Emory University, Atlanta, GA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sara Freeman
2Behavioral Neuroscience, Emory University, Atlanta, GA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ronald Voll
1Radiology, Emory University, Atlanta, GA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jeff Stehouwer
1Radiology, Emory University, Atlanta, GA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Larry Young
2Behavioral Neuroscience, Emory University, Atlanta, GA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mark Goodman
1Radiology, Emory University, Atlanta, GA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
Loading

Abstract

1503

Objectives Development of PET or SPECT radioligands for oxytocin receptors of the brain would be ideal for psychopharmacological studies of human and non-human primates in understanding the neurobiological mechanisms underlying the behavioral effects of the oxytocin receptor system. The compounds [125I]-(E)-1-(1-(2-(2-((3-iodoallyl)oxy)-4-((1-(methylsulfonyl)piperidin-4-yl)oxy)phenyl)acetyl)piperidin-4-yl)-3,4-dihydroquinolin-2(1H)-one (1) and [125I]-(Z)-1-(1-(2-(2-((3-iodoallyl)oxy)-4-((1-(methylsulfonyl)piperidin-4-yl)oxy)phenyl)acetyl)piperidin-4-yl)-3,4-dihydroquinolin-2(1H)-one (2) and their cold reference standards were synthesized and evaluated as potential PET or SPECT radioligands.

Methods Two tributylstannyl precursors for iodination, (E) and (Z)-1-(1-(2-(4-((1-(methylsulfonyl)piperidin-4-yl)oxy)-2-((3-(tributylstannyl)allyl)oxy)phenyl)acetyl)piperidin-4-yl)-3,4-dihydroquinolin-2(1H)-one were synthesized in twelve steps. Iodination was performed with [125I]- sodium iodide in the presence of H2O2 and HCl. In vitro autoradiography on prairie vole brain slices and lipophilicity measurements were performed with 1 and 2. Competitive binding assays were performed in vitro using prairie vole brain slices, the cold standard of 1, and selective, high-affinity I-125 labeled oxytocin or vasopressin peptides.

Results Compounds 1 and 2 were synthesized with radiochemical yields of 59% and 16% respectively with radiochemical purities ranging from 92.7 - 96%. The log P values were 2.36 for 1 and 2.18 for 2. Autoradiography data confirmed binding to the oxytocin receptor in the nucleus accumbens. Compound 1 outcompeted peptides for the oxytocin and vasopressin receptors and both ki values are being confirmed through additional binding assays.

Conclusions Compounds 1 and 2 displayed similar characteristics in binding specificity and selectivity. Lipophilicity was optimal for penetration to the brain. Both structures are viable candidates for further in vivo research.

Research Support NSF IBN-N876754 R0016

Previous
Back to top

In this issue

Journal of Nuclear Medicine
Vol. 51, Issue supplement 2
May 2010
  • Table of Contents
  • Index by author
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Synthesis and evaluation of I-125 quinolinone analogues as potential oxytocin receptor biomarkers
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
Synthesis and evaluation of I-125 quinolinone analogues as potential oxytocin receptor biomarkers
Aaron Smith, Sara Freeman, Ronald Voll, Jeff Stehouwer, Larry Young, Mark Goodman
Journal of Nuclear Medicine May 2010, 51 (supplement 2) 1503;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Synthesis and evaluation of I-125 quinolinone analogues as potential oxytocin receptor biomarkers
Aaron Smith, Sara Freeman, Ronald Voll, Jeff Stehouwer, Larry Young, Mark Goodman
Journal of Nuclear Medicine May 2010, 51 (supplement 2) 1503;
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
  • Info & Metrics

Related Articles

  • No related articles found.
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

Radiopharmaceutical Chemistry: New Radiopharmaceuticals-Neurosciences

  • Revisiting [18F]FHMP for imaging MAO-B
  • Effect of cocaine and amphetamine on 18FDG uptake by murine heart and brown adipose tissue (BAT)
Show more Radiopharmaceutical Chemistry: New Radiopharmaceuticals-Neurosciences

New Radiopharmaceuticals-Neurosciences Posters

  • Revisiting [18F]FHMP for imaging MAO-B
  • Highly efficient production of [18F]fallypride with low concentration of base
  • Synthesis, fluorine-18 labeling and radiopharmacological evaluation of novel 5-HT7 receptor antagonists
Show more New Radiopharmaceuticals-Neurosciences Posters

Similar Articles

SNMMI

© 2025 SNMMI

Powered by HighWire